Background: Ovarian cancer, the most lethal among gynecological malignancies, often presents at an advanced stage, complicating initial diagnosis and treatment planning. Imaging techniques, notably 18F-FDG PET/CT, have emerged as pivotal tools in the post-therapeutic evaluation of ovarian malignancies, aiding in accurate staging, recurrence detection, and therapeutic planning. This study aimed to evaluate the role of whole-body 18F-FDG PET/CT in detecting the loco-regional recurrence and distant metastasis in ovarian cancer patients. Methods: This study was carried out in private radiology centers from May 2022 to February 2023 for known patients of ovarian cancers underwent therapy, coming for annual follow up with suspected recurrence, and/or distant metastasis clinically or laboratory. Our study included 25 patients all of them performed PET- CT and diagnosed with ovarian malignant lesions underwent surgical management followed by chemotherapy, however their annual tumor marker assessment showed elevated CA 125 and were referred for PETCT assessment. Results: PET- CT was found to be more sensitive in detecting the peritoneal deposits (less than 5 mm in diameter) especially the peripherally located perihepatic ones which couldn't be detected by the CT or CE-CT images, in 5 cases out of 25 (20%).